Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. more
Time Frame | SLRN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.79% | -3.39% | 0.2% |
1-Month Return | -24.73% | -1.92% | 2.72% |
3-Month Return | -20.09% | -10.54% | 7.31% |
6-Month Return | -16.86% | -4.47% | 10.44% |
1-Year Return | -51.99% | 4.06% | 27.53% |
3-Year Return | -80.56% | 0.94% | 30.88% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | - | - | 115.00K | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | - | - | (115.00K) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-11500000,"profit":false}] | ||
Gross Margin | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Operating Expenses | 41.79M | 254.68M | 422.06M | [{"date":"2021-12-31","value":9.9,"profit":true},{"date":"2022-12-31","value":60.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (41.79M) | (254.68M) | (422.06M) | [{"date":"2021-12-31","value":-4179400000,"profit":false},{"date":"2022-12-31","value":-25468100000,"profit":false},{"date":"2023-12-31","value":-42206400000,"profit":false}] | ||
Total Non-Operating Income/Expense | (45.00K) | 8.58M | 70.98M | [{"date":"2021-12-31","value":-0.06,"profit":false},{"date":"2022-12-31","value":12.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Pre-Tax Income | (41.84M) | (250.46M) | (381.64M) | [{"date":"2021-12-31","value":-4183900000,"profit":false},{"date":"2022-12-31","value":-25046100000,"profit":false},{"date":"2023-12-31","value":-38164100000,"profit":false}] | ||
Income Taxes | (41.79K) | (4.17M) | (52.90K) | [{"date":"2021-12-31","value":-4179400,"profit":false},{"date":"2022-12-31","value":-417000000,"profit":false},{"date":"2023-12-31","value":-5289500,"profit":false}] | ||
Income After Taxes | (41.80M) | (246.29M) | (381.59M) | [{"date":"2021-12-31","value":-4179720600,"profit":false},{"date":"2022-12-31","value":-24629100000,"profit":false},{"date":"2023-12-31","value":-38158810500,"profit":false}] | ||
Income From Continuous Operations | (41.84M) | (250.46M) | (381.64M) | [{"date":"2021-12-31","value":-4183900000,"profit":false},{"date":"2022-12-31","value":-25046100000,"profit":false},{"date":"2023-12-31","value":-38164100000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (41.84M) | (250.46M) | (381.64M) | [{"date":"2021-12-31","value":-4183900000,"profit":false},{"date":"2022-12-31","value":-25046100000,"profit":false},{"date":"2023-12-31","value":-38164100000,"profit":false}] | ||
EPS (Diluted) | - | - | (4.35) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-435,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
SLRN | |
---|---|
Cash Ratio | 6.74 |
Current Ratio | 7.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SLRN | |
---|---|
ROA (LTM) | -32.89% |
ROE (LTM) | -41.95% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SLRN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SLRN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.64 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.46 |
ACELYRIN, INC. Common Stock (SLRN) share price today is $3.24
Yes, Indians can buy shares of ACELYRIN, INC. Common Stock (SLRN) on Vested. To buy ACELYRIN, INC. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLRN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of ACELYRIN, INC. Common Stock (SLRN) via the Vested app. You can start investing in ACELYRIN, INC. Common Stock (SLRN) with a minimum investment of $1.
You can invest in shares of ACELYRIN, INC. Common Stock (SLRN) via Vested in three simple steps:
The 52-week high price of ACELYRIN, INC. Common Stock (SLRN) is $8.88. The 52-week low price of ACELYRIN, INC. Common Stock (SLRN) is $3.14.
The price-to-earnings (P/E) ratio of ACELYRIN, INC. Common Stock (SLRN) is
The price-to-book (P/B) ratio of ACELYRIN, INC. Common Stock (SLRN) is 0.64
The dividend yield of ACELYRIN, INC. Common Stock (SLRN) is 0.00%
The market capitalization of ACELYRIN, INC. Common Stock (SLRN) is $338.10M
The stock symbol (or ticker) of ACELYRIN, INC. Common Stock is SLRN